ACNU Feasibility

View full report
GoodArexvy, an intramuscular RSV vaccine for adults 60+, shows moderate side effects, low misuse risk, manageable drug interactions, and requires post-vaccination monitoring, with simple single-dose adherence but complex administration and special population considerations.

ACNU Feasibility Scorecard

Chart with 11 data points.
Arexvy
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 8.
End of interactive chart.